Does the media refer more to MRK or SMMT?

In the previous week, Merck & Co., Inc. had 56 more articles in the media than Summit Therapeutics. MarketBeat recorded 64 mentions for Merck & Co., Inc. and 8 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 1.02 beat Summit Therapeutics' score of 0.39 indicating that Merck & Co., Inc. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merck & Co., Inc. 43 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Positive Summit Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, SMMT or LPA?

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A Logistic Properties of the Americas $50.13M 1.82 $10.50M N/A N/A

Is ARGX or SMMT more profitable?

argenex has a net margin of 31.31% compared to Summit Therapeutics' net margin of 0.00%. argenex's return on equity of 33.28% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 33.28% 28.16% Summit Therapeutics N/A -291.24% -243.07%

Does the media prefer ARGX or SMMT?

In the previous week, Summit Therapeutics had 1 more articles in the media than argenex. MarketBeat recorded 8 mentions for Summit Therapeutics and 7 mentions for argenex. argenex's average media sentiment score of 0.63 beat Summit Therapeutics' score of 0.39 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Do analysts recommend TAK or SMMT?

Summit Therapeutics has a consensus target price of $26.05, indicating a potential upside of 72.89%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Summit Therapeutics 3 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.39

Does the media favor TAK or SMMT?

In the previous week, Summit Therapeutics had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Summit Therapeutics and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.09 beat Summit Therapeutics' score of 0.39 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Summit Therapeutics (SMMT) Competitors

$15.07 +0.21 (+1.41%)

Closing price 04:00 PM Eastern

Extended Trading

$14.95 -0.12 (-0.82%)

As of 04:36 PM Eastern

Compare

SMMT vs. MRK, LPA, ARGX, TAK, and TEVA

Should you buy Summit Therapeutics stock or one of its competitors? MarketBeat compares Summit Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Summit Therapeutics include Merck & Co., Inc. (MRK), Logistic Properties of the Americas (LPA), argenex (ARGX), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA).

How does Summit Therapeutics compare to Merck & Co., Inc.?

Merck & Co., Inc. (NYSE:MRK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Merck & Co., Inc. has a net margin of 13.59% compared to Summit Therapeutics' net margin of 0.00%. Merck & Co., Inc.'s return on equity of 27.55% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	13.59%	27.55%	10.73%
Summit Therapeutics	N/A	-291.24%	-243.07%

In the previous week, Merck & Co., Inc. had 56 more articles in the media than Summit Therapeutics. MarketBeat recorded 64 mentions for Merck & Co., Inc. and 8 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 1.02 beat Summit Therapeutics' score of 0.39 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	43 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Positive
Summit Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Merck & Co., Inc. has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, meaning that its stock price is 232% less volatile than the broader market.

76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.2% of Merck & Co., Inc. shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Merck & Co., Inc. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.01B	4.37	$18.25B	$3.55	32.37
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Merck & Co., Inc. presently has a consensus price target of $128.18, suggesting a potential upside of 11.53%. Summit Therapeutics has a consensus price target of $26.05, suggesting a potential upside of 72.89%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.68
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

Summary

Merck & Co., Inc. beats Summit Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Summit Therapeutics (NASDAQ:SMMT) and Logistic Properties of the Americas (NYSEAMERICAN:LPA) are related companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 42.7% of Logistic Properties of the Americas shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 32.0% of Logistic Properties of the Americas shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summit Therapeutics presently has a consensus target price of $26.05, indicating a potential upside of 72.89%. Logistic Properties of the Americas has a consensus target price of $7.50, indicating a potential upside of 160.42%. Given Logistic Properties of the Americas' higher probable upside, analysts plainly believe Logistic Properties of the Americas is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Logistic Properties of the Americas	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Summit Therapeutics had 8 more articles in the media than Logistic Properties of the Americas. MarketBeat recorded 8 mentions for Summit Therapeutics and 0 mentions for Logistic Properties of the Americas. Logistic Properties of the Americas' average media sentiment score of 0.82 beat Summit Therapeutics' score of 0.39 indicating that Logistic Properties of the Americas is being referred to more favorably in the news media.

Company	Overall Sentiment
Summit Therapeutics	Neutral
Logistic Properties of the Americas	Positive

Logistic Properties of the Americas has a net margin of 6.31% compared to Summit Therapeutics' net margin of 0.00%. Logistic Properties of the Americas' return on equity of 1.08% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Logistic Properties of the Americas	6.31%	1.08%	0.49%

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Logistic Properties of the Americas	$50.13M	1.82	$10.50M	N/A	N/A

Summit Therapeutics has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market. Comparatively, Logistic Properties of the Americas has a beta of 5.28, suggesting that its share price is 428% more volatile than the broader market.

Summary

Logistic Properties of the Americas beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to argenex?

argenex (NASDAQ:ARGX) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, Summit Therapeutics had 1 more articles in the media than argenex. MarketBeat recorded 8 mentions for Summit Therapeutics and 7 mentions for argenex. argenex's average media sentiment score of 0.63 beat Summit Therapeutics' score of 0.39 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

argenex has a net margin of 31.31% compared to Summit Therapeutics' net margin of 0.00%. argenex's return on equity of 33.28% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
Summit Therapeutics	N/A	-291.24%	-243.07%

argenex has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.90	$1.29B	$22.46	36.20
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

argenex presently has a consensus price target of $1,019.50, indicating a potential upside of 25.38%. Summit Therapeutics has a consensus price target of $26.05, indicating a potential upside of 72.89%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

argenex has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, meaning that its stock price is 232% less volatile than the broader market.

60.3% of argenex shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

argenex beats Summit Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Summit Therapeutics compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.69	$1.27B	$0.39	38.50
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

In the previous week, Summit Therapeutics had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Summit Therapeutics and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.09 beat Summit Therapeutics' score of 0.39 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summit Therapeutics has a consensus target price of $26.05, indicating a potential upside of 72.89%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Takeda Pharmaceutical has a net margin of 4.31% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 11.07% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
Summit Therapeutics	N/A	-291.24%	-243.07%

Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market.

Summary

Takeda Pharmaceutical beats Summit Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Summit Therapeutics (NASDAQ:SMMT) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Summit Therapeutics. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 8 mentions for Summit Therapeutics. Teva Pharmaceutical Industries' average media sentiment score of 1.37 beat Summit Therapeutics' score of 0.39 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	14 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Summit Therapeutics' net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Summit Therapeutics currently has a consensus price target of $26.05, indicating a potential upside of 72.89%. Teva Pharmaceutical Industries has a consensus price target of $41.78, indicating a potential upside of 27.69%. Given Summit Therapeutics' higher probable upside, research analysts plainly believe Summit Therapeutics is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Teva Pharmaceutical Industries has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Teva Pharmaceutical Industries	$17.26B	2.18	$1.41B	$1.33	24.60

Summit Therapeutics has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats Summit Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Summit Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMMT vs. The Competition

Export

Metric	Summit Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.70B	$2.91B	$6.25B	$12.42B
Dividend Yield	N/A	1.79%	2.69%	5.29%
P/E Ratio	-9.42	17.67	22.28	24.19
Price / Sales	N/A	743.00	581.86	138.32
Price / Cash	N/A	56.38	42.31	57.88
Price / Book	17.73	3.85	9.84	6.72
Net Income	-$1.08B	$75.85M	$3.57B	$337.19M
7 Day Performance	-13.19%	-1.69%	-1.15%	0.53%
1 Month Performance	-6.46%	22.16%	3.85%	5.10%
1 Year Performance	-26.92%	21.78%	27.43%	34.36%

Summit Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMMT Summit Therapeutics	2.148 of 5 stars	$15.07 +1.4%	$26.05 +72.9%	-16.2%	$11.70B	N/A	N/A	110	Analyst Forecast
MRK Merck & Co., Inc.	4.4743 of 5 stars	$118.49 -1.2%	$128.18 +8.2%	+52.0%	$296.11B	$65.01B	33.38	75,000	Trending News High Trading Volume
LPA Logistic Properties of the Americas	3.4363 of 5 stars	$2.97 +2.8%	$7.50 +152.5%	-63.4%	$91.38M	$50.13M	29.70	30
ARGX argenex	4.1932 of 5 stars	$835.99 -0.3%	$1,017.78 +21.7%	+37.2%	$52.14B	$4.25B	37.22	1,863	Analyst Forecast
TAK Takeda Pharmaceutical	3.6636 of 5 stars	$15.97 -1.1%	N/A	+0.8%	$51.40B	$28.32B	40.94	47,455

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMMT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, ARGX, TAK, and TEVA

How does Summit Therapeutics compare to Merck & Co., Inc.?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Summary

How does Summit Therapeutics compare to argenex?

Summary

How does Summit Therapeutics compare to Takeda Pharmaceutical?

Summary

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, ARGX, TAK, and TEVA

How does Summit Therapeutics compare to Merck & Co., Inc.?

Is MRK or SMMT more profitable?

Does the media refer more to MRK or SMMT?

Which has more risk and volatility, MRK or SMMT?

Do institutionals & insiders hold more shares of MRK or SMMT?

Which has stronger valuation & earnings, MRK or SMMT?

Do analysts recommend MRK or SMMT?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Do insiders & institutionals believe in SMMT or LPA?

Do analysts recommend SMMT or LPA?

Does the media favor SMMT or LPA?

Is SMMT or LPA more profitable?

Which has preferable valuation and earnings, SMMT or LPA?

Which has more volatility and risk, SMMT or LPA?

Summary

How does Summit Therapeutics compare to argenex?

Does the media prefer ARGX or SMMT?

Is ARGX or SMMT more profitable?

Which has higher valuation & earnings, ARGX or SMMT?

Do analysts recommend ARGX or SMMT?

Which has more risk & volatility, ARGX or SMMT?

Do institutionals and insiders have more ownership in ARGX or SMMT?

Summary

How does Summit Therapeutics compare to Takeda Pharmaceutical?

Which has better valuation & earnings, TAK or SMMT?

Does the media favor TAK or SMMT?

Do analysts recommend TAK or SMMT?

Do institutionals & insiders believe in TAK or SMMT?

Is TAK or SMMT more profitable?

Which has more risk and volatility, TAK or SMMT?

Summary

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Does the media prefer SMMT or TEVA?

Is SMMT or TEVA more profitable?

Do analysts prefer SMMT or TEVA?

Which has higher valuation and earnings, SMMT or TEVA?

Which has more volatility & risk, SMMT or TEVA?

Do institutionals & insiders believe in SMMT or TEVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools